

# **NEW METHODS FOR ANTIBIOTICS DISCOVERY AND MOLECULAR MECHANISM CHARACTERIZATION**

**TECHNICAL JOURNAL CLUB**

**06/09/2022**

**STEFANO SELLITTO**


# THE URGENCY OF NEW ANTIBIOTICS REQUIRES NEW METHODOLOGIES

- High-throughput in vitro screens are consolidated approaches to discover antibiotic compounds, but the current profiling methods are limited in either the number of measurable parameters or throughput.
- Also de novo predictions of compound functionality with unconventional Modes of Action (MoAs) is fundamental to challenge the problem of new antibiotic-resistant bacteria and for the finding of effective multidrug combinations against bacterial infections.
- Molecular profiling of small molecules offers invaluable insights into the function of compounds and allows for hypothesis generation about small-molecule direct targets and secondary effects **partially bypassing the request for animal research.**




# Combining CRISPRi and metabolomics for functional annotation of compound libraries


Miquel Anglada-Girotto<sup>1,4</sup>, Gabriel Handschin<sup>1,4</sup>, Karin Ortmayr<sup>1</sup>, Adrian I. Campos<sup>1</sup>, Ludovic Gillet<sup>1</sup>, Pablo Manfredi<sup>2</sup>, Claire V. Mulholland<sup>3</sup>, Michael Berney<sup>3</sup>, Urs Jenal<sup>2</sup>, Paola Picotti<sup>1</sup> and Mattia Zampieri<sup>1</sup>✉






# GENETIC PERTURBATIONS INDUCE MEASURABLE METABOLIC CHANGES




# FUNCTIONAL ASSOCIATIONS BETWEEN GENE KNOCKDOWNS AND MAJOR ANTIBIOTIC CLASSES



# METABOLIC PROFILING OF CHEMICAL AND GENETIC PERTURBATIONS IN HUMAN CELLS







# DE NOVO PREDICTION OF ANTIMICROBIAL MoAs




Glycyls  
 Fal  
 Glycine, serine and th  
 Valine, leucine and iso  
 Phenylalanine, tyrosine and try  
 D-Glutamine and D-gli  
 Lipopolysac  
 Peptidic  
 C5-Branched diba  
 Ri  
 Terpenoid bac  
 Aminoacy  
 Biosyn

2-Oxocarboxy

Fatty acid metabolism  
 Biosynthesis of amino acids  
 ABC transporters  
 Quorum sensing  
 Ribosome  
 Protein export  
 Bacterial secretion system



# DE NOVO PREDICTION OF ANTIMICROBIAL MoAs






# Conclusions

- The combined gene–drug metabolic profiling approach provides a high-throughput platform for unbiased and rapid functional annotation of compound libraries
- Directly measuring the metabolic consequences of drug treatment can unravel mechanistic insights on the MoA of compounds that do not directly bind to proteins
- This approach is highly flexible and can be applied in virtually any type of system or conditions

## Clinically relevant mutations in core metabolic genes confer antibiotic resistance






Allison J. Lopatkin<sup>1,2,3,4,5,6</sup>, Sarah C. Bening<sup>1,2</sup>, Abigail L. Manson<sup>2</sup>, Jonathan M. Stokes<sup>1,2,3</sup>, Michael A. Kohanski<sup>7</sup>, Ahmed H. Badran<sup>2</sup>, Ashlee M. Earl<sup>2</sup>, Nicole J. Cheney<sup>8,9</sup>, Jason H. Yang<sup>8,9</sup>, James J. Collins<sup>1,2,3,10,11,\*</sup>




# EVOLVING ANTIBIOTIC RESISTANCE USING THE CLASSICAL APPROACH

| Drug  | Time point |           |
|-------|------------|-----------|
|       | Mid        | End       |
| Strep | P:3, C:0   | P:3, C:12 |
| Cipro | P:3, C:0   | P:3, C:12 |
| Carb  | P:3, C:0   | P:3, C:12 |
| Ctrl  | P:3, C:0   | P:3, C:4  |


P: populations      C: clones




# EVOLVING ANTIBIOTIC RESISTANCE USING THE CLASSICAL APPROACH



# EVOLVING ANTIBIOTIC RESISTANCE USING THE METABOLIC APPROACH




# GENE ONTOLOGY ENRICHMENT ANALYSIS DIFFERS BETWEEN EVOLUTIONS






# METABOLIC MUTATIONS ARE HIGHLY PREVALENT IN E. COLI GENOMES AND CONFER RESISTANCE


A




B



C



# KNOCKOUT AND OVEREXPRESSION CONFIRM GENETIC UNDERPINNINGS OF ANTIBIOTIC RESISTANCE





# Conclusions

- Metabolic mutations arise in response to antibiotic treatment, and these mutations confer resistance and are highly prevalent in clinical pathogens, suggests that canonical mutations may not be as representative, nor the mechanisms as comprehensive, as previously thought.
- Implementing new protocols to increase the accessible evolutionary pathways could facilitate the discovery of new resistance mechanisms and thereby enhance our ability to limit the development and spread of antibiotic resistance.

**Thank you for your attention**